

Tabelecleucel for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease: Effectiveness and Value

Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. All of the organizations and individuals below have been invited to provide input, however, it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- Atara Biotherapeutics
- ASTCT (American Society for Transplantation and Cellular Therapy)
- Children's Oncology Group
- Leukemia & Lymphoma Society
- National Kidney Foundation
- NORD (National Organization for Rare Disorders)
- Pierre-Fabre Laboratoires

We spoke with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having spoken with ICER:

- **Dr. Sarah Nikiforow, MD, PhD**, Medical Oncologist, Dana-Farber Cancer Institute, Harvard Medical School
- **Dr. Jean Koff, MD, MS**, Associate Professor, Department of Hematology and Medical Oncology, Emory Winship Cancer Institute
- **Dr. Keri Toner, MD**, Oncologist, Children's National Hospital

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).